Impact of Gene Polymorphism on Pharmacokinetics and Pharmacodynamics of Calcium Channel Blockers: A Narrative Review

A class of drugs known as calcium channel blockers (CCBs) is used to treat hypertension, angina, and arrhythmias. There are two subcategories of this medication class: dihydropyridines and non-dihydropyridines. Studies on CYP3A5*3, AGTR1 rs275653, ABCB1 (MDR1) rs1045642, and POR*28 A503V have all investigated the effects of SNPs on CCBs. In this study, further research will be conducted to determine which SNPs most influence the efficacy of CCBs. The narrative reviews in this article come from a variety of sources. We performed searches in Pubmed, ScienceDirect, and Google Scholar using the terms "calcium channel blocker," "efficacy," "blood pressure response," "pharmacokinetic," and "polymorphism" OR "genetic" OR "genomic" to find relevant articles. When prescribing antihypertensive drugs, especially calcium channel blockers, it is essential to consider specific gene variants, for example, CYP3A5*3/*3, CYP3A4 *1G/*1G, MDR1 C3435T, RyR3 gene rs877087, because of their significant effects. Copyright © 2023 by Indonesian Journal of Pharmacy (IJP).